Enzo Biochem Inc. (ENZ: Quote) announced that it has made its first peer-reviewed presentation of its novel AmpiProbe platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays, at the annual meeting in London of the European Society of Clinical Microbiology and Infectious Diseases or ESCMID.
The company said its presentation, titled "Quantitative Detection of HCV RNA in Human Plasma-Serum using the Enzo AmpiProbe HCV RNA Assay," detailed the specifications and performance characteristics of the first diagnostic product developed utilizing the AmpiProbe platform.
Enzo's AmpiProbe Hepatitis C virus RNA assay was tested over hundreds of clinical samples and found to be reproducible, accurate and precise, the presentation indicated. In addition, the AmpiProbe HCV RNA assay was found, as compared to similar diagnostics products, to achieve a greater enhanced sensitivity that allows for a more convenient and efficient workflow requiring significantly less starting material.
by RTT Staff Writer
For comments and feedback: email@example.com